A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma

BACKGROUND: Mitogen-activated protein kinase kinase (MEK) is activated by mutated KRAS in >90% of pancreatic ductal adenocarcinoma (PDAC). MEK and focal adhesion kinase (FAK) are frequently co-activated in PDAC providing a rationale for combining trametinib, an oral allosteric MEK1/2 inhibitor, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Aung, Kyaw L., McWhirter, Elaine, Welch, Stephen, Wang, Lisa, Lovell, Sophia, Stayner, Lee-Anne, Ali, Saara, Malpage, Anne, Makepeace, Barbara, Ramachandran, Makilpriya, Jang, Gun Ho, Gallinger, Steven, Zhang, Tong, Stockley, Tracy L., Fischer, Sandra E., Dhani, Neesha, Hedley, David, Knox, Jennifer J., Siu, Lillian L., Goodwin, Rachel, Bedard, Philippe L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830369/
https://www.ncbi.nlm.nih.gov/pubmed/36636049
http://dx.doi.org/10.21037/jgo-22-86

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830369/
https://www.ncbi.nlm.nih.gov/pubmed/36636049
http://dx.doi.org/10.21037/jgo-22-86

Ejemplares similares